Enantioselective synthesis revealedoral efficacy for (S)-9 in animal models.Compound 9 behavior bolsters the interest of a small-moleculePAM of GLP-1R as a promising therapeutic approach for the increasinglyprevalent obesity-associated diabetes. Here, GLP1R is linked to diabetes mellitus.